NCT07190222 - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Biotech Hunter

Enrollment

942

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

November 27, 2029

Study Completion Date

January 22, 2030

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Lunsekimig

Pharmaceutical form: solution for injection in prefilled syringe - Route of administration: Subcutaneous injection

DRUG

Placebo

Pharmaceutical form:s olution for injection - Route of administration: Subcutaneous injection

Trial Locations (13)

6017

RECRUITING

Investigational Site Number : 0360001, Osborne Park

32825

RECRUITING

Florida Institute for Clinical Research, LLC- Site Number : 8400001, Orlando

33186

RECRUITING

Innovations Biotech- Site Number : 8400019, Miami

33467

RECRUITING

Finlay Medical Research- Site Number : 8400107, Greenacres City

33470

RECRUITING

Pulmonary Specialists of the Palm Beaches- Site Number : 8400017, Loxahatchee Groves

48116

RECRUITING

Bolt Clinical Research- Site Number : 8400086, Brighton

75254

RECRUITING

IntraCare- Site Number : 8400034, Dallas

80228

RECRUITING

Critical Care, Pulmonary and Sleep Associates- Site Number : 8400081, Lakewood

85712

RECRUITING

Tucson Clinical Research Institute- Site Number : 8400006, Tucson

89119

RECRUITING

AB Clinical Trials - Site Number : 8400075, Las Vegas

V1Y 4N7

RECRUITING

Investigational Site Number : 1240051, Kelowna

G6P 6P6

RECRUITING

Investigational Site Number : 1240042, Victoriaville

S61 1AH

RECRUITING

Investigational Site Number : 8260017, Rotherham